ARS Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

SPRY$3.57+13.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue:
Product revenue, net	$568	$—	$568	$—
Revenue under collaboration agreements	1,500	—	2,000	30
Total revenue	2,068	—	2,568	30
Operating expenses:
Cost of goods sold	112	—	112	—
Research and development (including related party amounts of $406, $307, $1,651 and $1,382, respectively)	4,423	3,002	16,553	16,862
Selling, general and administrative (including related party amounts of $129, $322, $337 and $840, respectively)	19,281	14,976	36,183	40,462
Total operating expenses	23,816	17,978	52,848	57,324
Loss from operations	(21,748)	(17,978)	(50,280)	(57,294)
Other income, net	2,620	3,112	8,344	10,097
Net loss	$(19,128)	$(14,866)	$(41,936)	$(47,197)
Change in unrealized gains and losses on available-for-sale securities	484	19	290	(568)
Comprehensive loss	$(18,644)	$(14,847)	$(41,646)	$(47,765)
Net loss per share, basic and diluted	$(0.20)	$(0.16)	$(0.43)	$(0.50)
Weighted-average shares outstanding used in computing net loss per share, basic and diluted	97,032,331	95,576,627	96,782,818	94,910,012

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.